Subcutaneous Tarlatamab Shows Safety and Early Activity in Small Cell Lung Cancer
A phase 1b study presented at the IASLC 2026 World Conference on Lung Cancer found that subcutaneous tarlatamab was well ...
A phase 1b study presented at the IASLC 2026 World Conference on Lung Cancer found that subcutaneous tarlatamab was well ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine